Arrowhead Pharmaceuticals (ARWR) Leases (2016 - 2025)
Historic Leases for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $43.4 million.
- Arrowhead Pharmaceuticals' Leases fell 336.09% to $43.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $43.4 million, marking a year-over-year decrease of 336.09%. This contributed to the annual value of $43.9 million for FY2025, which is 301.4% down from last year.
- According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' Leases is $43.4 million, which was down 336.09% from $43.9 million recorded in Q3 2025.
- Arrowhead Pharmaceuticals' Leases' 5-year high stood at $96.3 million during Q2 2023, with a 5-year trough of $33.1 million in Q1 2021.
- Over the past 5 years, Arrowhead Pharmaceuticals' median Leases value was $44.2 million (recorded in 2024), while the average stood at $47.7 million.
- As far as peak fluctuations go, Arrowhead Pharmaceuticals' Leases soared by 7253.9% in 2021, and later tumbled by 5397.85% in 2024.
- Arrowhead Pharmaceuticals' Leases (Quarter) stood at $42.0 million in 2021, then rose by 0.1% to $42.0 million in 2022, then rose by 6.88% to $44.9 million in 2023, then decreased by 0.08% to $44.9 million in 2024, then dropped by 3.36% to $43.4 million in 2025.
- Its Leases was $43.4 million in Q4 2025, compared to $43.9 million in Q3 2025 and $44.0 million in Q2 2025.